5 курс / Психиатрия и наркология для детей и взрослых (доп.) / КЛИНИЧЕСКАЯ_ПСИХОФАРМАКОГЕНЕТИКА

1.De Hert M., van Eyck D., De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring // IntClinPsychopharmacol. 2006;

21:11–15. doi:10.1097/01.yic.0000201496.23259.85.

2.Kubo M., Koue T., Inaba A., Takeda H., Maune H., Fukuda T., Azuma J. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole

14.Vermeir M., Naessens I., Remmerie B., Mannens G., Hendrickx J., Sterkens P. et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans // Drug Metabolism and Disposition. 2008; 36(4): 769-79. doi:10.1124/dmd.107.018275.

15.He H., Richardson J.S. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT and dopamine D receptors // International clinical psychopharmacology.

doi:10.2133/dmpk.20.55.

3. Shin J.G., Kane K., Flockhart D.A. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol // British Journal of Clinical Pharmacology. 2008; 51(1), 45–52. doi:10.1046/j.13652125.2001.01313.x.

00003.

16.Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics // The Journal of clinical psychiatry. 1996.57(11): 12-25. PMID: 8941167.

17.Wong S.L., Linnen P., Mack R., Granneman G.R. Effects of food, antacid, and dosage form on the

Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution // Drug Metabolism and Disposition. 2011; 40(2), 240–248. doi:10.1124/dmd.111.042150.

5. Narayanan, Rangaraj& Leduc, Barbara & Williams, David. (2004). Glucuronidation of haloperidol by rat liver microsomes: Involvement of family 2 UDPglucuronosyltransferases. Life sciences. 74. 2527-39. 10.1016/j.lfs.2003.10.009.

6. Sandson N.B., Armstrong S.C., Cozza K.L. An overview of psychotropic drug-drug interactions // Psychosomatics. 2005; 46(5): 464–94. doi:10.1176/appi. psy.46.5.464.

7. Davies S.J., Westin A.A., Castberg I., Lewis G., Lennard M.S., Taylor S. et al. Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies // Acta PsychiatricaScandinavica. 2010; 122(6): 445–453. doi:10.1111/j.1600-0447.2010.01619.x.

8.Brunton L., Chabner B., Knollman B. Goodman and Gilman’s the pharmacological basis of therapeutics // New York, ed 12, 2010. – 406 p. ISBN 978-0071624428.

9.Urichuk L., Prior T., Dursun S., Baker G. Metabolism of Atypical Antipsychotics: Involvement of Cytochrome P450 Enzymes and Relevance for Drug-Drug Interactions // Current Drug Metabolism. 2008; 9(5): 410-

418.doi:10.2174/138920008784746373.

10.Mori A. Udp-Glucuronosyltransferase 1A4

Polymorphisms In A Japanese Population And Kinetics Of Clozapine Glucuronidation // Drug Metabolism and Disposition. 2005; 33(5): 672-675. doi:10.1124/ dmd.104.002576.

11.OkuboM.,NaritaM.,MurayamaN.,AkimotoY.,Goto A., Yamazaki H. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3 // Human Psychopharmacology: Clinical and Experimental. 2016; 31(2): 83-92. doi:10.1002/ hup.2515.

12.Söderberg M.M, Haslemo T., Molden E., Dahl M.L. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients

//The pharmacogenomics journal. 2013; 13(6): 544-550. doi:10.1038/tpj.2012.47.

13.Bigos K.L., Bies R.R., Pollock B.G., Lowy J.J., Zhang F., Weinberger D.R. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance // Molecular psychiatry. 2011; 16(6): 620-625. doi:10.1038/ mp.2011.38.

in healthy volunteers // Biopharmaceutics & Drug Disposition. 1997; 18(6): 533-41. doi:10.1002/(sici)1099- 081x(199708)18:6<533::aid-bdd42>3.0.co;2-j.

18.Wagstaff A.J., Fitton A., Benfield P. Sulpiride // Cns Drugs. 1994; 2(4): 313-33. doi:10.2165/00023210- 199402040-00007.

19.Dose M., Lange H.W. The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes // Pharmacopsychiatry. 2000; 33(1): 19–27. doi:10.1055/s-2000-7964.

20.Midha K.K., Korchinski E.D., Verbeeck R.K., Roscoe R.M., Hawes E.M., Cooper J.K. et al. Kinetics

of oral trifluoperazine disposition in man // British journal of clinical pharmacology. 1983; 15(3): 380-382. doi:10.1111/j.1365-2125.1983.tb01515.x.

21.20. Gunes A., Dahl M. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms // Pharmacogenomics. 2008; 9(5): 625-637. doi:10.2217/14622416.9.5.625.

22.21. Uchaipichat V., Mackenzie P.I., Elliot D.J., Miners J.O. Selectivity of substrate (trifluoperazine)

glucuronosyltransferases // Drug metabolism and disposition. 2006; 34(3): 449-456. doi:10.1124/ dmd.105.007369.

23. Jørgensen A. A sensitive and specific radioimmunoassay for cis (Z)-flupenthixol in human serum // Life sciences. 1978; 23(15): 1533-42. doi:10.1016/0024- 3205(78)90580-5.

24. Jorgensen A., Hansen V., Dahl Larsen U., Khan A.R. Metabolism, distribution and excretion of flupenthixol // Acta Pharmacol. 1969; 27: 301-313. doi:10.1111/j.1600-0773.1969.tb00516.x.

25.Jaworski T.J., Hawes E.M., McKay G., Midha,

K.K. The Metabolism of Chlorpromazine N-Oxide in the Rat // Xenobiotica. 1988; 18(12): 1439–1447. doi:10.3109/00498258809042266.

26. Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Five distinct human cytochromes mediate amitriptyline N demethylation in vitro: dominance of CYP 2C19 and 3A4 // The Journal of Clinical Pharmacology. 1998; 38(2): 112-21. doi:10.1002/j.1552-4604.1998.tb04399.x.

27. Liu X., Lu Y.F., Guan X., Zhao M., Wang J., Li F. Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches // Biochemical pharmacology. 2016;109:70-82.

doi:10.1016/j.bcp.2016.03.020.

28.\ OttonS.V.,BallS.E.,CheungS.W.,InabaT.,Rudolph R.L., Sellers E.M. Venlafaxine oxidationinvitroiscatalysed by CYP2D6 // British Journal of Clinical Pharmacology. 1996; 41(2): 149–56. doi:10.1111/j.1365-2125.1996.tb00173.x.

29.\ Fogelman S.M., Schmider J., Venkatakrishnan K., von Moltke L.L., Harmatz J.S., Shader R.I., Greenblatt D.J. O-and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

from human sources // Drug metabolism and disposition. 1998;26(6): 572-5. doi:10.1016/s0006-3223(97)00483-6.

43.\ Overmars H., Scherpenisse P.M., Post L.C. Fluvoxamine maleate: metabolism in man // Eur J Drug MetabPharmacokinet. 1983; 8:259-80. doi:10.1007/ bf03188757.

44.\ van Harten J. Overview of the pharmacokinetics of fluvoxamine // ClinPharmacokinet. 1995; 29(1):1-9. doi:10.2165/00003088-199500291-00003.

45.\ Mandrioli R., Forti G.C., Raggi M.A. Fluoxetine

doi:10.1016/s0893-133x(98)00113-4.

30.\ Hvenegaard M.G., Bang-Andersen B., Pedersen H., Jørgensen M., Püschl A., Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004

//Drug Metabolism and Disposition. 2012; 40(7):1357-65. doi:10.1124/dmd.112.044610.

31.\ Lobo E.D., Bergstrom R.F., Reddy S., Quinlan T., Chappell J., Hong Q., Ring B., Knadler M.P. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine // Clinical pharmacokinetics. 2008; 47(3): 191202. doi:10.2165/00003088-200847030-00005.

32.\ Sigg E.B. Pharmacological Studies with Tofrānil // Canadian Psychiatric Association Journal. 1959; 4(1): 75– 85. doi:10.1177/070674375900401s07.

33.\ Tanaka E. Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes. Journal of clinical pharmacy and therapeutics // 1998; 23(6): 403-16. doi:10.1046/j.1365-2710.1998.00086.x.

34.\ Koyama E., Chiba K., Tani M., Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers

//Journal of Pharmacology and Experimental Therapeutics. 1996;278(1):21-30.doi:10.2133/dmpk.9.supplement_148.

35.\ Li F., Chin C., Wangsa J., Ho J. Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride // Drug Metabolism and Disposition. 2012; 40(9): 1723-1735. doi:10.1124/ dmd.112.045120.

36.\ Puozzo C., Lens S., Reh C., Michaelis K., Rosillon D., DeroubaixX.,DeprezD.Lackofinteractionofmilnacipranwith the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants // Clinical pharmacokinetics. 2005; 44(9): 977-988. doi:10.2165/00003088-200544090- 00007.

37.\ Hussar D.A. New drugs: Milnacipran hydrochloride, fesoterodine fumarate, and silodosin. Journal of the American Pharmacists Association. 2009;49(2):347-50. doi:10.1331/japha.2009.09509.

38.\ Zhou S.F., Zhou Z.W., Yang L.P., Cai J.P. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development //Curr Med Chem. 2009;16(27):3480-675. doi:10.2174/092986709789057635

39.\ Jornil J., Jensen K.G., Larsen F., Linnet K. Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator //Drug Metabolism and Disposition. 2009; 38(3): 376–385. doi:10.1124/dmd.109.030551.

40.\ Ronfeld R.A., Wilner K.D., Baris B.A. Sertraline. Clinical Pharmacokinetics. 1997; 32(1): 50–55. doi:10.2165/00003088-199700321-00008.

41.\ Obach, R. S. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study // Drug Metabolism and Disposition. 2004; 33(2): 262–270. doi:10.1124/dmd.104.002428.

cytochrome p450 // Current drug metabolism. 2006; 7(2): 127-33. doi:10.2174/138920006775541561.

46.\ Sangkuhl K., Klein T.E., Altman R.B.PharmGKB summary: citalopram pharmacokinetics pathway // Pharmacogenetics and Genomics. 2011; 21 (11): 769–72. doi:10.1097/FPC.0b013e328346063f.

47.\ Rochat B., Kosel M., Boss G. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver //BiochemPharmacol. 1998; 56 (1): 15-23. doi:10.1016/s0006-2952(98)00008-2.

48.\ vonMoltkeLL,GreenblattDJ,GiancarloGM,Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metabolism and Disposition. 2001 Aug 1;29(8):1102-9. PMID: 11454728.

49.\ Sidhu J., Priskorn M., Poulsen M., Segonzac A., Grollier G., Larsen F. Steady state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans // Chirality. 1997; 9(7): 686-92. doi:10.1002/(sici)1520- 636x(1997)9:7<686::aid-chir9>3.0.co;2-5.

50.\ Ghodke-Puranik Y., Thorn C.F., Lamba J.K., Leeder J.S., Song W., Birnbaum A.K. et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2013 Apr;23(4):236. doi:10.1097/fpc.0b013e32835ea0b2.

51.\ Pearce R.E., Lu W., Wang Y.Q., Uetrecht J.P., Correia M.A., Leeder J.S. Pathways of сarbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine // Drug Metabolism and Disposition, 2008; 36(8): 1637-1649. doi:10.1124/dmd.107.019562.

52.\ Kerr B.M., Thummel K.E., Wurden C.J., Klein S.M., Kroetz D.L., Gonzalez F.J. et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation // BiochemPharmacol. 1994; 47(11): 1969–79. doi:10.1016/0006-2952(94)90071-x.

53.\ Pelkonen O., Myllynen P., Taavitsainen A. R., Boobis P., Watts B. G. Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems // Xenobiotica. 2001; 31(6): 321–43. doi:10.1080/00498250110055479.

54.\ Kang P., Liao M., Wester M.R., Leeder J.S., Pearce R.E., Correia M.A.CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile // Drug MetabDispos. 2008;36(3):490–9. doi:10.1124/dmd.107.016501.

55.\ López M., Dorado P., Monroy N., Alonso M.E., Jung-Cook H., Machín E. et al. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine // Drug metabolism and drug interactions. 2011;26(1):5-12. doi:10.1515/dmdi.2011.008.

56.\ Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics // Pharmacology & therapeutics. 2000; 85(2):77-85. doi:10.1016/s0163- 7258(99)00052-2

57.\ Caldwell G.W., Wu W.N., Masucci J.A., McKown L.A., Gauthier D., Jones W.J. et al. Metabolism and excretion of the antiepileptic/antimigraine drug, topiramate in animals

403

and humans. European journal of drug metabolism and pharmacokinetics. 2005 Sep 1;30(3):151-64. doi:10.1007/ bf03190614.

58. Saivin S., Hulot T., Chabac S., Potgieter A., Durbin P., Houin G. Clinical pharmacokinetics of acamprosate

64. Obach R.S., Reed-Hagen A.E., Krueger S.S., Obach B.J., O'Connell T.N., Zandi K.S. et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro // Drug Metabolism and Disposition. 2006; 34 (1): 121–30.

doi:10.2165/00003088-199835050-00001.

59.Wuis E.W., Dirks M.J.M., Termond E.F.S., Vree T.B., Kleijn E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects // European Journal of Clinical Pharmacology. 1989; 37 (2): 181–84. doi:10.1007/ BF00558228.

60.Gruber V.A., McCance-Katz E.F. Methadone, buprenorphine, andstreet drug interactionswith antiretroviral medications // Current HIV/AIDS Reports. 2010; 7(3): 152-

160.doi:10.1007/s11904-010-0048-2.

61.Kirchheiner J., Klein C., Meineke I., Sasse J., Zanger U.M., Mürdter T.E. et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6 // Pharmacogenetics and Genomics. 2003; 13(10): 619-626. doi:10.1097/00008571-200310000-00005.

62.Zhu A.Z.X., Zhou Q., Cox L.S., Ahluwalia J.S., Benowitz N.L., Tyndale R.F. Gene Variants in CYP2C19 Are Associated with Altered In Vivo Bupropion Pharmacokinetics but Not Bupropion-Assisted Smoking Cessation Outcomes // Drug Metabolism and Disposition. 2014; 42(11): 1971– 1977. doi:10.1124/dmd.114.060285.

63.Meyer A., Vuorinen A., Zielinska A.E., Strajhar P., Lavery G.G., Schuster D., Odermatt A. Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase // Drug Metabolism and Disposition. 2013; 41(9): 1671–8. doi:10.1124/ dmd.113.052936.

65.Emery M.G., Jubert C., Thummel K E., Kharasch E.D. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans // Journal of Pharmacology and Experimental Therapeutics. 1999; 291(1), 213-219. doi:10.1124/jpet.102.049072.

66.Anaheim O.M., Moksnes K., Borchgrevink P.C., Kaasa S., Dale O. Clinical pharmacology of methadone for pain // Acta AnaesthesiologicaScandinavica. 2008; 52 (7): 879–89. doi:10.1111/j.1399-6576.2008.01597.x.

67.Keating G.M. Nalmefene: a review of its use in the treatment of alcohol dependence // CNS drugs. 2013; 27(9): 761-772. doi:10.1007/s40263-013-0101-y.

68.Porter S.J., Somogyi A.A., White J.M. Kinetics and inhibition of the formation of 6β naltrexol from naltrexone in human liver cytosol // British journal of clinical pharmacology. 2000; 50(5): 465-471. doi:10.1046/j.13652125.2000.00281.x.

69.Stamer U.M., Lee E.H., Rauers N.I., Zhang L., Kleine-Brueggeney M., Fimmers R. et al. CYP2D6-and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care // Anesthesia& Analgesia. . 2011; 113(1): 48-54. doi:10.1213/ ane.0b013e31821d01bc.

70.Bockbrader H.N., Wesche D., Miller R., Chapel S., Janiczek N., Burger P. A comparison of the pharmacokinetics

and pharmacodynamics of pregabalin and gabapentin // Clinical Pharmacokinetics. 2010; 49(10): 661–669. doi:10.2165/11536200-000000000-00000.